"InSphero Launches Industry's First Automation-compatible 3D Human Liver Disease Platform for NASH Drug Discovery and Screening"
InSphero AG today announced a breakthrough in 3D cell technology for drug discovery and safety testing with the launch of its 3D InSight™ Human Liver Disease Discovery Platform for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The platform has been precisely engineered to include all the human liver cell types and inducers necessary to replicate progression of NASH in patients, from fatty liver to inflammation and scarring of the liver. “Modelling all the elements of this human disease has been extremely challenging,” said Scott Friedman, MD, chief of liver diseases at the Icahn School of Medicine at Mount Sinai. He added, “Drug screens with animal models of NASH can take months and do not always accurately reflect whether a drug will work on humans. InSphero's platform offers a possible alternative for rapid screening of large numbers of drugs and combinations of drugs at different doses."
— Scott L. Friedman, MD, Dean, Therapeutic Discovery, Professor, Department of Medicine, Liver Diseases, Pharmacological Sciences, Chief, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai